Publications > Journals > Journal of Exploratory Research in Pharmacology > Special Feature

Time: May 25, 2022


Journal: Journal of Exploratory Research in Pharmacology

Special Issue: Novel Therapeutic Interventions for Neurodegenerative Disorders

Guest Editor: Prof. Ramón Cacabelos

Status: Open

Submission deadline: November 30, 2022

Publication date: An article will be published online as soon as it is accepted.


Guest Editor’s Profile:


Image

Ramón Cacabelos, MD, PhD

After graduating in Medicine and Surgery from the Faculty of Medicine of the University of Oviedo, Prof. Ramón Cacabelos began his professional career in the Department of Psychiatry at Osaka University (Japan), where he specialized in Neuropsychiatry and obtained a Doctorate in Medical Sciences (Internal Medicine and Psychiatry) (DMSci). He has a second doctorate in Medicine and Surgery (Ph.D.) from the University of Santiago de Compostela. 

He was appointed the first Professor of Genomic Medicine in Europe at Camilo José Cela University in Madrid, where he also held the position of Vice-Chancellor for Research and Science. He founded the Spanish Society of Genomic Medicine, the World Association of Genomic Medicine and the Spanish Association of Medical Nutraceuticals. In his long scientific career, he has directed hundreds of national and international research projects, collaborating with leading Asian, European, and American scientists. In addition to this, he has authored more than 2000 publications and 30 books; is a member of 100 scientific and medical societies; is a referee for 100s of international scientific journals, Editor-in-Chief of more than 20 national and international medical and scientific journals, and an editor of the first world guide to pharmacogenomics (World Guide for Drug Use and Pharmacogenomics, EuroEspes Publishing Co., 2012) and the first treatise on Pharmacoepigenetics (Pharmacoepigenetics) (Academic Press/Elsevier, 2019). 

His medical activity, as Director of the International Centre for Neuroscience and Genomic Medicine in Spain, and his corporate responsibilities, as President of the EuroEspes Group, are combined with his Chair in Genomic Medicine at the Faculty of Medicine of the Continental University in Peru and his scientific work as Professor at the Sechenov University in Moscow. Throughout his professional career, he has been awarded with numerous distinctions. 


The most common neurodegenerative disorders (NDDs) in developed countries are Alzheimer’s disease (AD) and Parkinson’s disease (PD), though over 50 different NDDs are known to affect the general population. Dementia and PD are among the top 15 conditions with the highest increase in disease burden in recent years, and an estimated 45–50 million people currently suffer from dementia with predicted increases to 75 million by 2030 and 145 million by 2050 based on the diagnosis of 7.7 million new cases/year. The prevalence of PD ranges from 35.8 per 100,000 to 12,500 per 100,000, with an annual incidence ranging from 1.5 per 100,000 to 346 per 100,000 in different countries. PD has been found to coexist with dementia and depression in over 25% of cases. In addition to different forms of dementia and Parkinson-like disorders, other NNDs of clinical relevance include demyelinating disorders and motor-neuron disease.

The cost-effectiveness of interventions for most brain disorders ranges between US$100 and US$2000 per healthy life year gained. However, drug effectiveness is lower than 30% for most neuropsychiatric disorders, which may coexist with NDDs.

AD and PD, along with many other NDDs, share some common features, including (i) polygenic/complex defects in conjunction with epigenetic changes, cerebrovascular dysfunction and environmental risk factors; (ii) age-related onset, with prevalence increasing in parallel with age; (iii) a progressive neuronal degeneration that begins in early periods of life, with clinical manifestation occurring decades later; (iv) conformational changes in proteins responsible for the abnormal deposition of neurotoxic byproducts; (v) lack of specific biomarkers for a predictive diagnosis and/or early detection; and (vi) no curative treatments.

This Special Issue of JERP provides an open door to new ideas and initiatives on the pathogenic mechanisms underlying NNDs, which will be the basis for future treatments that will be more effective than those we currently have.

Therefore, we invite all interested authors to contribute their ideas in this intellectual platform offered by JERP to young researchers and experts in NNDs to motivate and stimulate research and the search for new therapeutic alternatives for the treatment of NDDs. Potential topics include, but are not limited to:

  • Pathogenesis of Alzheimer’s disease 
  • Pathogenesis of Parkinson’s disease 
  • Pathogenesis of other neurodegenerative disorders 
  • Genomics 
  • Epigenetics 
  • Biomarkers 
  • Preventive strategies 
  • Novel treatments 
  • Pharmacogenetics 

 

Authors should refer to the Instructions for Authors  in preparing  the manuscript and kindly submit it through the Online Submission System directly.

 

Priority will be given with the same high standards of peer review and publication process for these articles. Authors publishing papers regarding nanodrug delivery systems for cancer treatment will not be charged any fees, and all publications will be available with free open access to all readers. Additionally, all accepted papers related to nanodrug delivery systems for cancer treatment will be highlighted in a special section on our website.

 

Online submission system: https://www.publinexh.com/ 

Article processing charge: None

Instructions for authors: Please state in a cover letter that the manuscript is being submitted for inclusion in the special issue ‘Novel Therapeutic Interventions for Neurodegenerative Disorders’, and follow the usual JERP instructions. Please refer to: https://www.xiahepublishing.com/journal/jerp/instruction

For any inquiries, please contact the journal by e-mail: [email protected]